1. Home
  2. STVN vs GRFS Comparison

STVN vs GRFS Comparison

Compare STVN & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Stevanato Group S.p.A.

STVN

Stevanato Group S.p.A.

N/A

Current Price

$14.72

Market Cap

5.2B

ML Signal

N/A

Logo Grifols S.A.

GRFS

Grifols S.A.

N/A

Current Price

$8.58

Market Cap

5.2B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
STVN
GRFS
Founded
1949
1940
Country
Italy
Spain
Employees
N/A
N/A
Industry
Containers/Packaging
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.2B
5.2B
IPO Year
2021
2008

Fundamental Metrics

Financial Performance
Metric
STVN
GRFS
Price
$14.72
$8.58
Analyst Decision
Buy
Buy
Analyst Count
13
2
Target Price
★ $24.84
$10.37
AVG Volume (30 Days)
361.4K
★ 585.5K
Earning Date
11-03-2026
07-28-2022
Dividend Yield
0.31%
★ 1.24%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$6.91
$2.02
Revenue Next Year
$8.95
$6.02
P/E Ratio
$27.15
★ $18.67
Revenue Growth
N/A
N/A
52 Week Low
$12.89
$6.96
52 Week High
$27.00
$9.77

Technical Indicators

Market Signals
Indicator
STVN
GRFS
Relative Strength Index (RSI) 21.78 74.93
Support Level $13.80 $7.52
Resistance Level $17.19 $8.83
Average True Range (ATR) 0.86 0.19
MACD -0.23 0.11
Stochastic Oscillator 16.54 95.87

Price Performance

Historical Comparison
STVN
GRFS

About STVN Stevanato Group S.p.A.

Stevanato Group is a provider of glass and polymer drug containment, drug delivery, and diagnostic solutions to the pharmaceutical and life sciences industries. The company operates through two segments: a Biopharmaceutical and Diagnostic Solutions segment, which offers an integrated, end-to-end portfolio of products, processes, and services spanning the full drug lifecycle; and an Engineering segment, which designs, develops, and manufactures advanced machinery for pharmaceutical manufacturing, covering visual inspection, assembly and packaging, glass converting, and serialization. Stevanato's revenue is geographically diversified, with approximately 60% of sales generated in Europe, the Middle East, and Africa, 30% in North America, 8% in Asia-Pacific, and 2% in South America.

About GRFS Grifols S.A.

Grifols SA is a healthcare company engaged in activities related to plasma-derived products and diagnostic solutions. The group has four reportable segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma segment focuses on products derived from human plasma for therapeutic use, while the Diagnostic segment includes the marketing of diagnostic testing equipment and reagents. The Bio Supplies segment covers biological products for non-therapeutic use and plasma sales to third parties, and the Others segment includes manufacturing services, research activities, and complementary pharmaceutical products.

Share on Social Networks: